FDA/NIH GENE THERAPY DATABASE FUTURE FUNDING IN QUESTION, CBER's NOGUCHI CAUTIONS RAC IN MEMO; CANCER GENE THERAPY, RARE DISEASE AND AIDS PROTOCOLS OKed
Future funding for the collaborative gene therapy database being created by FDA and the National Institutes of Health may be in jeopardy, FDA Division of Cellular and Gene Therapies Director Philip Noguchi, MD, warned in a memorandum presented to the National Institutes of Health Recombinant DNA Advisory Committee at its June 8-9 meeting in Bethesda, Md.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth